Search results
Results from the WOW.Com Content Network
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [5] It is delivered subcutaneously either by injection or from an insulin pump. [5] [6] Onset of effects typically occurs within 30 minutes and lasts about 5 hours. [5]
Faster-acting insulins peak quickly and are subsequently metabolized, while longer-acting insulins tend to have extended peak times and remain active in the body for more significant periods. [5] Examples of rapid-acting insulins (peak at ~1 hour) are: [citation needed] Insulin lispro (Humalog) Insulin aspart (Novolog) Insulin glulisine (Apidra)
Ultralente insulin was a long-acting form of insulin.It has an onset of 4 to 6 hours, a peak of 14 to 24 hours, and a duration of 28 to 36 hours. [1] Ultralente insulin, along with lente insulin, were discontinued in the US by manufacturers in the mid-2000s.
Insulin was first used as a medication in Canada by Charles Best and Frederick Banting in 1922. [85] [86] This is a chronology of key milestones in the history of the medical use of insulin. For more details on the discovery, extraction, purification, clinical use, and synthesis of insulin, see Insulin
Insulin Lispro Injection was also priced 50% lower than the list price of Humalog U-100. Lilly said that since then 10% of people using Humalog have transitioned to the cheaper injection.
The condition is also referred to as insulin-dependent diabetes, meaning exogenous insulin injections must replace the insulin the pancreas is no longer capable of producing for the body's needs. Type 1 is the most common form of diabetes in dogs and affects approximately 0.34% of dogs .
The market size for fast-acting insulin is well worth a second chance. Eli Lilly 's ( NYS: LLY ) Humalog insulin sales, for instance, reached almost $2.4 billion in fiscal 2011. 2.
Eli Lilly said on Wednesday it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year.